Trial Profile
An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs TA 270 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Pharmacodynamics
- 02 Jun 2011 New trial record